HEATR1, ZNF185, and SMAD4 could affect the chemosensitivity of gemcitabine and may be the indicators of gemcitabine selection in the chemotherapy of pancreatic cancer. This evidence concerns the gene SMAD4 and pancreatic neoplasm.